Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

BACKGROUND: Cabazitaxel is approved in patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-containing regimen. This study evaluated a weekly cabazitaxel dosing regimen. Primary objectives were to report dose-limiting toxicities (DLTs) and to determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fumoleau, Pierre, Trigo, Jose Manuel, Isambert, Nicolas, Sémiond, Dorothée, Gupta, Sunil, Campone, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854123/
https://www.ncbi.nlm.nih.gov/pubmed/24099585
http://dx.doi.org/10.1186/1471-2407-13-460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854123/
https://www.ncbi.nlm.nih.gov/pubmed/24099585
http://dx.doi.org/10.1186/1471-2407-13-460

Ejemplares similares